The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

CareDx to Divest Lab Products Business for $170 Million in Cash

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1CareDx agreed to divest its Lab Products business to EuroBio Scientific for $170 million in cash.

about 2 months ago

Version History

Version 3about 2 months ago

What changed: Added details regarding board approval and the projected timeline for the deal's closure.

Version 2about 2 months ago

What changed: Confirmed the buyer's identity (Eurobio Scientific) and added the strategic rationale for the acquisition along with the official signing date.

Version 1about 2 months ago

What changed: Added QuidelOrtho's preliminary Q1 2026 revenue results and updated full-year financial guidance.

French company Eurobio Scientific has officially signed a definitive agreement to acquire CareDx's Lab Products division for $170 million in cash. The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the third quarter of 2026. This acquisition is designed to accelerate Eurobio's strategy to become a global leader in in-vitro molecular diagnostics (IVD). Meanwhile, QuidelOrtho Corporation released preliminary Q1 2026 revenue, with full financial results expected on May 5. The divestiture allows CareDx to sharpen its focus on transplant precision medicine while significantly strengthening its balance sheet. These developments highlight a period of intense strategic realignment within the global diagnostics sector.